SOPHiA GENETICS partners with Microsoft to accelerate the analysis of multimodal health data

Agreement aims to extend and strengthen data-driven medicine through the SOPHiA DDM™ healthcare data analytics platform available with Microsoft Azure

GENEVA, November 1, 2022 /PRNewswire/ — SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native healthcare software company, embarks on a multi-year integrated strategic partnership with Microsoft to improve healthcare workflows globally . This investment in the development of next-generation healthcare will lead the way in enabling the curation, development and deployment of multimodal data. As a result, the SOPHiA DDM™ platform powered by Microsoft Azure is expected to elevate the standard of care for patients, delivering advanced results for precision medicine.

The SOPHiA GENETICS global network breaks down data silos, enabling the democratization of data-driven medicine by connecting institutions that operate diverse multimodal datasets on the SOPHiA DDM™ platform. Multimodal healthcare datasets can be the largest and most complex to structure, analyze, and archive, and this far-reaching partnership will focus on accelerating results, improving performance, and ultimately, improving medical research by propelling the transition to precision medicine on a global scale.

“With the scale of Microsoft and the power of the SOPHiA DDM™ platform, this partnership will help improve clinical outcomes and make patient care more efficient and personalized,” said Jurgi Camblong, PhD., co-founder and CEO of SOPHiA GENETICS. “SOPHiA GENETICS will help accelerate the transition to a decentralized model of care for hospitals, healthcare providers and biopharma by breaking down data silos and delivering innovations at scale.

“SOPHiA GENETICS’ mission is to democratize data-driven medicine. Microsoft is pleased to support this mission by providing a secure and scalable cloud infrastructure, alongside SOPHiA GENETICS’ advanced artificial intelligence and machine learning tools and technologies that can help generate actionable insights, which can lead to better health outcomes,” said David C. Rhew, MD, Microsoft Global Medical Director.

This strategic partnership strengthens the collaboration between SOPHiA GENETICS and Microsoft. SOPHiA GENETICS offers its SOPHiA DDM™ AI and machine learning platform on Azure, leveraging various Azure services that enable greater efficiency and open up opportunities to advance tools to unlock medical data and important genomics. With the addition of the SOPHiA DDM™ platform, providers using Azure will expand their ability to aggregate multimodal data types to extract insights into existing workflows to deliver the best care possible. As one of Microsoft’s chosen partners for precision medicine, SOPHiA GENETICS will help accelerate the transition to a decentralized care model for hospitals, healthcare providers and biopharma, by breaking down data silos and delivering innovations at scale.

SOPHiA GENETICS products are for research use only and should not be used in diagnostic procedures unless otherwise specified. The information in this press release relates to products that may or may not be available in different countries and, where applicable, may or may not have received marketing approval or clearance from a government regulatory body for different indications for use. please contact [email protected] to obtain the appropriate product information for your country of residence.


SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life science research. He is the creator of the SOPHiA DDM™ platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal datasets and different diagnostic modalities. The SOPHiA DDM™ platform and associated solutions, products and services are currently used by an extensive network of hospitals, laboratories and biopharmaceutical institutions around the world. For more information, visit SOPHiAGENETICS.COM or log on to TwitterLinkedIn, Facebook, and Instagram. Where others see data, we see answers.

SOPHiA GENETICS forward-looking statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future operating results and financial condition, business strategy, products and technology, and plans and objectives for direction for future operations, are forward-looking statements. . Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. These statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by the forward-looking statements due to a variety of factors, including those described in our filings with the Securities and Exchange. United States Commission. No assurance can be given that these future results will be achieved. These forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update any forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions or circumstances on which such statements are based, unless required to do so. by the rights. No representation or warranty (express or implied) is made as to the accuracy of these forward-looking statements.

Quote View original content for multimedia download:


Comments are closed.